A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). I was asked to discuss the topic on ...

Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.

Doctors might be slow to admit it, but Ozempic and other GLP-1 drugs are making dieting and exercise obsolete.

A new analysis estimates that losing as little as 5% weight can lead to substantial savings in health care costs elsewhere.

Experts are divided on the subject, however. While some suggest that even small doses of Ozempic could suppress appetite, there is little scientific data to support claims that microdosing leads to ...

Weight loss drugs such as Ozempic and Wegovy are increasingly popular among adults, who have flocked to the new medication as ...

Weight-loss drugs like Ozempic seem like a miracle. But they've also created a gold rush for online scammers and hucksters.

Thanks to effective and popular new drugs for weight loss and diabetes – an estimated 1 in 8 adults in the US has used ...

As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according to cybersecurity experts.